argenx to present at the LEERINK Partners 5th Annual Global Healthcare Conference
February 04, 2016
Breda, the Netherlands / Ghent, Belgium– argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that Chief Executive Officer, Tim Van Hauwermeiren, will present at the Leerink Partners 5th Annual Global Healthcare Conference in New York City (NY, USA) on Thursday, February 11, 2016 at 1:50pm ET.
The presentation will be webcast live and may be accessed via this link or by visiting the Company’s website www.argenx.com. A replay of this webcast will be available for 90 days following the presentation.
argenx combines the diversity of the llama immune system with antibody engineering to advance a clinical pipeline to treat patients with cancer and autoimmune diseases. Our platforms allow us to unlock novel and complex targets and develop antibody-based drugs designed for greater efficacy and longer duration of effect. The strength of our team, our deep understanding of the biology, and our committed collaborations with industry leaders contribute to the success of our journey.